Additional GLP-1 Analogue on CSII Treatment for Poorly Controlled Type 2 Diabetic Patients (AGAC2)
|ClinicalTrials.gov Identifier: NCT01473147|
Recruitment Status : Completed
First Posted : November 17, 2011
Last Update Posted : July 30, 2013
Background: Continuous subcutaneous insulin infusion (CSII) has been demonstrated to be an effective clinical tool for intensive insulin therapy in Type 1 diabetic patients. Type 2 diabetes patients have been proved to have decreased of glucagon-like peptide-1 (GLP-1) levels. Injection of GLP-1 receptor agonists are associated with improved glycemic control. Nevertheless, the clinical effects and mechanisms are still unclear when additional supplement of GLP-1 analogue in cooperation with intensive CSII treatment for poorly controlled Type 2 diabetes patients. This study is designed to understand the complementary pharmacological effects of GLP-1 analogue on intensive CSII treatment.
Methods: Sixty poorly controlled Type 2 diabetes patients will be admitted to the ward for 6 days CSII intensive treatment. Following the normalization of blood glucose at first 3 days, the patients are randomly assigned with combined therapy with exenatide injection or saline for another 3 days. The clinical assessments of insulin requirement, insulin secretion, insulin resistance glycemic excursions and cytokines will perform immediately during or after the study.
|Condition or disease||Intervention/treatment|
|Type 2 Diabetes Mellitus||Drug: Exenatide Drug: Normal saline|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||51 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Additional GLP-1 Analogue on CSII Treatment for Poorly Controlled Type 2 Diabetic Patients|
|Study Start Date :||October 2011|
|Primary Completion Date :||June 2013|
|Study Completion Date :||June 2013|
|Active Comparator: GLP-1||
Exenatide 5 microgram bid sc.
Other Name: Byetta
|Placebo Comparator: Normal saline||
Drug: Normal saline
Normal saline 2 u bid sc.
- Mean amplitude of glycaemic excursions (MAGE) [ Time Frame: During 6-day treatment course ]
- homeostasis model assessment(HOMA) [ Time Frame: During 6-day treatment course ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01473147
|Chang Gung Memorial Hospital|
|Taoyuan, Taiwan, 333|
|Principal Investigator:||CHIA-HUNG LIN, M.D.||Chang Gung Memorial Hospital|